TMDX Archives - BioTuesdays

Developments

TransMedics posts positive results from randomized OCS DCD heart trial

TransMedics Group (NASDAQ:TMDX) reported positive topline results from its OCS donors after circulatory death (DCD) heart trial. The OCS DCD heart trial was designed as the first and only randomized trial to compare...

November 4, 2021

Developments

FDA clears TransMedics transplant OCS Liver System

TransMedics Group (NASDAQ:TMDX) received premarket approval from the FDA of its OCS Liver System for use with organs from donors after brain and circulatory death. “We are extremely proud of this approval of our...

September 29, 2021

Developments

TransMedics receives positive FDA AdCom vote for OCS Liver System

The FDA’s Gastroenterology and Urology Devices Panel, after a review and discussion, issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Liver System. The panel voted 14-to-0...

July 15, 2021

Feature

TransMedics redefining what’s possible in organ transplantation

TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.

May 4, 2021

Developments

TransMedics receives positive FDA advisory committee vote for OCS Heart System

The FDA’s Circulatory Systems Device Advisory Panel issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Heart System to the FDA’s Office of Health Technology 2 (Cardiovascular...

April 7, 2021

Markets

Canaccord ups TransMedics PT to $79 from $46

Canaccord Genuity raised its price target for TransMedics Group (NASDAQ:TMDX) to $79 from $46, saying the company has the “technology that will become the standard of care for organ transplant and in the process...

March 15, 2021

Markets

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

March 3, 2021

Markets

Cowen ups TransMedics PT to $44 from $20

Cowen raised its price target for TransMedics (NASDAQ:TMDX) to $44 from $20, citing multiple catalysts ahead for all three of the company’s organ programs. The stock closed at $23.82 on Feb. 23. TransMedics has...

February 24, 2021

Developments

TransMedics reports positive topline results from liver transplant trial

TransMedics Group’s (NASDAQ:TMDX) pivotal Organ Care System (OCS) liver trial, called PROTECT, achieved its primary and secondary effectiveness and safety endpoints. TransMedics’ OCS technology addresses the major...

May 26, 2020

Tag - TMDX

TransMedics posts positive results from randomized OCS DCD heart trial

FDA clears TransMedics transplant OCS Liver System

TransMedics receives positive FDA AdCom vote for OCS Liver System

TransMedics redefining what’s possible in organ transplantation

TransMedics receives positive FDA advisory committee vote for OCS Heart System

Canaccord ups TransMedics PT to $79 from $46

Canaccord ups TransMedics PT to $46 from $20

Cowen ups TransMedics PT to $44 from $20

TransMedics reports positive topline results from liver transplant trial

General

More